BioCentury
ARTICLE | Clinical News

Amplimexon imexon: Phase II data

July 19, 2010 7:00 AM UTC

In the double-blind, U.S. Phase II AMP-019 trial in 142 patients, Amplimexon plus Gemzar gemcitabine missed the primary endpoint of significantly improving OS vs. placebo plus Gemzar (p=0.64). AmpliMed said the trial required a 40% improvement in OS to reach statistical significance, and the OS in each arm was about 6 months. Amplimexon was well tolerated. The company hopes to start a Phase II trial of Amplimexon as a single agent to treat relapsed or refractory non-Hodgkin's lymphoma (NHL) in 4Q10. ...